Weight loss, REDEFINE 1 and 2 trial dose (clinical trial)
Who: Adults with obesity or overweight (REDEFINE 1, n=3,417) or with type 2 diabetes (REDEFINE 2, n=1,206), plus diet and activity advice. Amounts are per component: the same mg of semaglutide goes with each mg of cagrilintide.
Timing: Both peptides stepped up together every 4 weeks, reaching 2.4 mg + 2.4 mg at week 17.
| When | Dose |
|---|---|
| Weeks 1 to 4 | 0.25 mg |
| Weeks 5 to 8 | 0.5 mg |
| Weeks 9 to 12 | 1 mg |
| Weeks 13 to 16 | 1.7 mg |
| Weeks 17 to 68 | 2.4 mg |
Note: REDEFINE 1 allowed people to stay on a lower dose: at week 68, 57.3% of CagriSema patients were on the top dose. No regulator has approved any CagriSema dose yet.